CTRI/2011/12/002225尚未招募1 期
A Phase 1 Dose-Escalation Study of the Safety andPharmacokinetics of Daily OCID 4681-S-01 Administered Orally to Subjects with Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 The subject has a histologically confirmed solid tumor that is metastatic or unresectable and is no longer responding to therapies known to prolong survival or to other standard therapies, or has disease for which no standard
- •therapy exists.
- •2 The subject is greater than or equal to 18 years old.
- •3 The subject has an Eastern Cooperative Oncology Group ECOG performance status of 0 to 2 Appendix B
- •4 Subject has a life expectancy of greater than 3 months.
- •5 The subject has adequate organ and marrow function as follows
- •Absolute neutrophil count ANC greater than or equal 1500mm3.
- •Platelets greater than or equal 100,000mm3.
- •Hemoglobin greater than or equal 10 g per dL, with no transfusions within the last seven days.
- •Bilirubin less than or equal 1.5 the upper limit of normal ULN.
- •Serum creatinine less than or equal 1.5 ULN or calculated creatinine clearance greater than or equal 60 mL per min.
- •Alanine aminotransferase ALT and aspartate aminotransferase AST
- •less than or equal 2.5 ULN if no liver involvement, or less than or equal 5 ULN with liver involvement.
- •6 The subject is able to swallow and tolerate oral medications such as capsules.
- •7 The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document.
- •8 Sexually active subjects men and women must agree to use medicallyaccepted barrier methods of contraception eg, male condom, female
- •condom, or diaphragm with spermicidal gel during the course of the study and for 3 months after the last dose of study drugs, even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control.
- •9 Women of childbearing potential must have a negative pregnancy test at screening. Women of childbearing potential include any woman who has
- •experienced menarche and who has not undergone successful surgical sterilization hysterectomy, bilateral tubal ligation, or bilateral oophorectomy or is not postmenopausal. Post menopause is defined as
- •Amenorrhea greater than or equal 12 consecutive months without another cause or
- •For women with irregular menstrual periods and on hormone replacement therapy, a documented serum follicle stimulating hormone FSH level 35 mIU per mL.
排除标准
- •1 The subject has received cytotoxic chemotherapy including investigational cytotoxic chemotherapy or biologic agents eg, cytokines or antibodies within 3 weeks, or nitrosoureas or
- •mitomycin C within 6 weeks before the first dose of study treatment.
- •2 The subject has received radiation therapy within 14 days of the first dose of study treatment. Palliative radiation to nonmarrow areas is allowed.
- •3 The subject has received any other type of investigational agent within 28 days before the first dose of study treatment.
- •4 The subject has not recovered from toxicity due to all prior therapies ie, return to pretherapy baseline or to Grade 0 or 1
- •5 The subject has received lifetime radiation to 25 percent of his or her bone marrow before the first dose of study treatment.
- •6 The subject has a primary brain tumor or brain metastases.
- •7 The subject has prothrombin time PT International Normalized Ratio INR or partial thromboplastin time PTT test results at screening that are 1.3 times the laboratory ULN.
- •8 The subject has uncontrolled significant intercurrent illness including, but not limited to ongoing or active infection, history of congestive heart failure within 6 months, uncontrolled hypertension or unstable angina pectoris within 6 months, stroke within 3 months, myocardial infarction within 3 months, or cardiac arrhythmias.
- •9 The subject is pregnant or breastfeeding.
- •10 The subject tests positive for the human immunodeficiency virus HIV, Hepatitis B virus (HBV) or Hepatitis C virus HCV at screening.
- •11 The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation.
- •12 The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
研究者
相似试验
已完成
不适用
A Phase I, Dose Escalation Study on the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) and its Comparability to NovoSeven® in Healthy Male Volunteers Pre-Treated with Fondaparinuxhaemophilia10064477NL-OMON34613Centre for Human Drug Research36
招募中
1 期
CAPRISA 012BHIV/AIDSPACTR202003767867253CAPRISA76
进行中（未招募）
1 期
A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus VulgarisPemphigus vulgarisMedDRA version: 20.0Level: LLTClassification code 10052802Term: Pemphigus vulgarisSystem Organ Class: 100000004858EUCTR2018-002146-37-ITINCYTE CORPORATIO18
进行中（未招募）
1 期
A study to test if increasing doses of the drug INCB050465 is safe and well tolerated in patients with Pemphigus VulgarisPemphigus vulgarisMedDRA version: 20.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858EUCTR2018-002146-37-FRIncyte Corporation18
已完成
1 期
Clinical trial to evaluate safety, tolerability and pharmacokinetic of herbal (ICB-014-A002) capsule in healthy adult volunteers.CTRI/2018/01/011259Indian Institute of Integrative Medicine Council of Scientific Industrial Research38